Title : Failure of tofacitinib to achieve an objective response in a DDX3X-MLLT10 T-lymphoblastic leukemia with activating JAK3 mutations.

Pub. Date : 2020 Aug

PMID : 32843425






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 We describe a case of relapsed T-ALL in an adult patient, with two JAK3 activating mutations identified by whole-exome sequencing (WES), leading to hypothesis-based treatment with the JAK1 and JAK3 inhibitor, tofacitinib, following failure of salvage chemotherapy reinduction. tofacitinib Janus kinase 3 Homo sapiens